Validation of an LC-MS Method for the Detection and Quantification of BZP and TFMPP and their Hydroxylated Metabolites in Human Plasma and its Application to the Pharmacokinetic Study of TFMPP in Humans

被引:30
作者
Antia, Ushtana [1 ]
Tingle, Malcolm D. [2 ]
Russell, Bruce R. [1 ]
机构
[1] Univ Auckland, Sch Pharm, Auckland 1, New Zealand
[2] Univ Auckland, Dept Pharmacol, Auckland 1, New Zealand
关键词
forensic science; toxicology; liquid chromatography-mass spectrometry; BZP; TFMPP; pharmacokinetics; metabolism; DRUG N-BENZYLPIPERAZINE; RATS;
D O I
10.1111/j.1556-4029.2010.01457.x
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
An LC-MS method was developed for benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP), constituents of "party pills" or "legal herbal highs," and their metabolites in human blood plasma. Compounds were resolved using a mixture of ammonium formate (pH 4.5, 0.01 M) and acetonitrile (flow rate of 1.0 mL/min) with a C18 column. Calibration curves were linear from 1 to 50 ng/mL (R2 > 0.99); the lower limit of quantification (LLOQ) was 5 ng/mL; the accuracy was > 90%; the intra- and interday relative standard deviations (R.S.D) were < 5% and < 10%, respectively. Human plasma concentrations of TFMPP were measured in blood samples taken from healthy adults (n = 6) over 24 h following a 60-mg oral dose of TFMPP: these peaked at 24.10 ng/mL (+/- 1.8 ng/mL) (C(max)) after 90 min (T(max)). Plasma concentrations of 1-(3-trifluoromethyl-4-hydroxyphenyl) piperazine peaked at 20.2 ng/mL (+/- 4.6 ng/mL) after 90 min. TFMPP had two disposition phases (t(1/2) = 2.04 h (+/- 0.19 h) and 5.95 h (+/- 1.63 h). Apparent clearance (Cl/F) was 384 L/h (+/- 45 L/h).
引用
收藏
页码:1311 / 1318
页数:8
相关论文
共 12 条
  • [1] [Anonymous], 2001, Guidance for industry, bioanalytical method validation
  • [2] Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants
    Antia, U.
    Lee, H. S.
    Kydd, R. R.
    Tingle, M. D.
    Russell, B. R.
    [J]. FORENSIC SCIENCE INTERNATIONAL, 2009, 186 (1-3) : 63 - 67
  • [3] Metabolic interactions with piperazine-based 'party pill' drugs
    Antia, Ushtana
    Tingle, Malcolm D.
    Russell, Bruce R.
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2009, 61 (07) : 877 - 882
  • [4] Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses
    Chambers, Erin
    Wagrowski-Diehl, Diane M.
    Lu, Ziling
    Mazzeo, Jeffrey R.
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 852 (1-2): : 22 - 34
  • [5] GORDON M, 2007, P INT AUSTR WINT C B
  • [6] LEE H, 2007, P INT AUSTR WINT C B
  • [7] Murphy M, 2009, NEW ZEAL MED J, V122, P16
  • [8] Rivière GJ, 2000, J PHARMACOL EXP THER, V292, P1042
  • [9] RUSSELL B, 2007, P INT AUSTR WINT C B
  • [10] Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP) -: In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes
    Staack, RF
    Paul, LD
    Springer, D
    Kraemer, T
    Maurer, HH
    [J]. BIOCHEMICAL PHARMACOLOGY, 2004, 67 (02) : 235 - 244